Oxford BioMedica wins second $100 million gene therapy contract – Reuters
City A.M. |
Oxford BioMedica wins second $100 million gene therapy contract
Reuters The deal follows a similar $100 million contract last year to supply lentiviral vectors, which are used to deliver DNA into cells, for Novartis's pioneering leukemia treatment Kymriah. Oxford Bio, which listed in London in 1996 after being spun out of … Oxford BioMedica share price rises on $100m gene therapy deal with Bioverativ Oxford BioMedica signs agreement with Bioverativ Oxford BioMedica Inks Potential USD100 Million Deal With Bioverativ |
